Diphtheria-Tetanus-Acellular Pertussis Combined Vaccine Biological Page (dtap)
|
|
- Marilynn Leonard
- 5 years ago
- Views:
Transcription
1 Diphtheria-Tetanus-Acellular Pertussis Cmbined Vaccine Bilgical Page (dtap) Sectin 7: Bilgical Prduct Infrmatin Standard #: Created by: Apprved by: Prvince-wide Immunizatin Prgram Standards and Quality Prvince-wide Immunizatin Prgram Standards and Quality Apprval Date: February 8, 2012 Revised: September 5, 2018 Adacel Manufacturer Sanfi Pasteur Limited GlaxSmithKline Inc. Bilgical Classificatin Indicatins fr Prvincially Funded Vaccine Inactivated Children 7 years up t and including 17 years f age: with an uncertain r n histry f a primary series r thse wh have nt cmpleted a primary series fr diphtheria, tetanus and pertussis Nte: If pli vaccine is als indicated cmbined dtap-ipv vaccine shuld be used. See Diphtheria-Tetanus-Acellular Pertussis-Pli Cnjugate Cmbined Vaccine Bilgical Page # wh are due fr a reinfrcing dse f diphtheria, tetanus and pertussis vaccine in grade 9 and have nt received a dse f acellular pertussis vaccine as an adlescent (i.e.,12 years up t and including 17 years f age) as part f the rutine schl immunizatin prgram wh are candidates r recipients f SOT - immunize using the rutine age apprpriate schedule fr tetanus-diphtheria-pertussis cntaining vaccine fr recipients f HSCT refer t Transplant Guidelines # t determine apprpriate tetanus-diphtheria-pertussis cntaining vaccine wh sustain a tetanus prne wund need t have their tetanus immunizatin histry assessed ( Tetanus Preventin, Prphylaxis and Wund/Injury Management Standard #08.400) Nte: Fr questins related t Travel and r Fr Sale vaccine refer t AHS Travel Health and Cntracted Immunizatin Services resurces. Ntes: Students in ungraded classes r thse wh d nt cntinue in the schl system t grade 9 can still be immunized n a case by case basis, generally at 14 years up t and including 18 years f age. The guiding principle shuld be t ffer prtectin t students prir t them leaving the schl system. Grade 9 students wh have received a dse f tetanus, diphtheria, acellular pertussis cntaining vaccine prir t 12 years f age shuld receive a dse f dtap in grade 9 regardless f the interval in rder t ensure best prtectin as an adlescent and adult. Grade 9 students wh have received a dse f Td (i.e., as part f wund management) shuld receive a dse f dtap vaccine regardless f the spacing. dtap vaccine may be prvided t acute care emergency departments and urgent care centers but will nt rutinely be prvided t physician ffices at this time. Children needing tetanus prphylaxis fr wund management shuld be referred t public health fr age-apprpriate tetanus cntaining vaccine. If this is nt pssible they shuld be prvided with available tetanus cntaining vaccine fr wund management and subsequently referred t Immunizatin Prgram Standards Manual Page 1 f 7
2 public health fr further assessment f immunizatin recmmendatins. See Tetanus Preventin, Prphylaxis and Wund/Injury Management Standard # ). Individuals 18 years f age and lder: Wh are initiating r cmpleting a primary series f tetanus-diphtheria cntaining vaccine shuld have ne dse in the Td series given as dtap vaccine. Wh have nt received an adult dse f dtap vaccine as they present fr service including pregnant wmen 26 weeks f gestatin r greater. effrts shuld be made t ffer an adult dse f dtap vaccine t health care wrkers with a pririty fr thse wh prvide care t children yunger than 12 mnths f age. In an utbreak situatin based n lcal r reginal epidemilgy the MOH may authrize: dtap fr pregnant wmen wh are 26 weeks gestatin r greater regardless f immunizatin histry with tetanus-diphtheria-pertussis cntaining vaccine and regardless f the interval frm the last tetanus/diphtheria r pertussis cntaining vaccine. priritizatin f dtap fr adults wh have cntact r anticipate cntact with infants and have nt received a dse f dtap as an adult (18 years f age and lder). Cnsideratin shuld be given t ffering dtap when pregnant wmen wh are 26 weeks gestatin r greater, irrespective f their immunizatin histry, travel t areas where pertussis is circulating. Fr candidates r recipients f SOT immunize using the rutine age apprpriate schedule fr tetanus-diphtheria-pertussis cntaining vaccine. Fr recipients f HSCT refer t Transplant Guidelines # t determine apprpriate tetanus-diphtheria-pertussis cntaining vaccine. Fr candidates r recipients f SOT immunize using the rutine age apprpriate schedule fr tetanus-diphtheria-pertussis cntaining vaccine. Wh sustain a tetanus prne wund need t have their tetanus immunizatin histry assessed (see Tetanus Preventin, Prphylaxis and Wund/Injury Management Standard #08.400). Clse cntacts (e.g. husehld, classrm) f a diphtheria case shuld receive a dse f a diphtheria txid-cntaining vaccine as apprpriate fr age unless the cntact is knwn t have been fully immunized fr age and the last dse f diphtheria txid-cntaining vaccine was given within 10 years. The diphtheria txid-cntaining vaccine series shuld be cmpleted fr previusly unimmunized r incmpletely immunized cntacts. Fr disease investigatin, cntact assessment and reprting requirements, refer t Public Health Ntifiable Disease Guidelines Diphtheria. Carriers f diphtheria, if nt previusly immunized, and thse f unknwn immunizatin status shuld receive immunizatin prmptly and ensure cmpletin f vaccine series. If a carrier has been immunized previusly but has nt received a bster f diphtheria txid within 10 years, a bster dse f a diphtheria txid-cntaining vaccine shuld be given. Infectin with diphtheria des nt necessarily cnfer immunity; therefre immunizatin shuld be given during cnvalescence frm diphtheria disease. Serlgy Pre-Immunizatin and Pst immunizatin There is n serlgical test available fr pertussis. Immunizatin Prgram Standards Manual Page 2 f 7
3 Serlgical testing is nt typically recmmended t assess levels f immunity t diphtheria r tetanus. Fr additinal infrmatin see the Alberta Health DAT/TAT Interpretatin tables. Schedule Preferred Use Dse Preparatin/ Recnstitutin Rute Cntraindicatins/ Precautins Primary Series fr eligible individuals: 7 years up t and including 17 years f age: Dse 1 day 0 Dse 2 4 t 8 weeks after dse 1 Dse 3 6 t 12 mnths after dse 2 18 years f age and lder: A single dse f dtap shuld be given t adults as part f a primary series f tetanus/diphtheria cntaining vaccine. Any remaining dses in the primary series shuld be given using Td vaccine ensuring the apprpriate spacing. Reinfrcing Dse: A single reinfrcing dse f dtap shuld be given t eligible children 12 years up t and including 17 years f age as utlined in the indicatins sectin (typically given in the grade 9 schl immunizatin prgram). A single reinfrcing dse f dtap shuld be given t adults 18 years f age and lder presenting fr a Td bster, if they have nt received a dse f dtap as an adult. Spacing Cnsideratins: In rder t prvide prtectin fr pertussis eligible individuals may receive a dse f dtap vaccine regardless f the spacing since the last dse f Td. Fr individuals being fllwed fr wund management see Tetanus Preventin, Prphylaxis and Wund/Injury Management Standard #08.400). Individuals wh have had tetanus, diphtheria r pertussis illness shuld still be immunized as these clinical infectins d nt always cnfer immunity. In Alberta, dtap is nt prvided t individuals less than 7 years f age. Individuals less than 7 years f age shuld receive the age apprpriate cmbined vaccines as per prvincial eligibility criteria. There will be n preference indicated fr the use f Adacel r in specific age r risk grups. Bth vaccines are safe and immungenic in individuals fur years f age and lder. Persns with medical cntraindicatins t ne prduct shuld be ffered the alternate prduct if supply is available. 0.5 ml See vaccine prduct mngraph IM Cntraindicatins: Knwn severe hypersensitivity t any cmpnent f the vaccine. Anaphylactic r ther allergic reactin t a previus dse f vaccine cntaining tetanus, diphtheria r pertussis antibdies. Immunizatin Prgram Standards Manual Page 3 f 7
4 Encephalpathy f unknwn etilgy (e.g., cma, decreased level f cnsciusness, prlnged seizures) within 7 days f a previus dse f a pertussis-cntaining vaccine. shuld nt be administered t individuals wh have experienced transient thrmbcytpenia fllwing a previus dse f diphtheria/tetanus cntaining vaccine. Cnsult with MOH n a case-by-case basis t determine immunizatin recmmendatins. Precautins: If Guillain-Barré Syndrme (GBS) ccurred within 6 weeks f immunizatin with a previus dse f vaccine cntaining tetanus txid, it is prudent t withhld subsequent dses f tetanus-cntaining vaccine. Thse wh develp GBS utside this interval r have an alternative cause identified may receive subsequent dses f tetanus-cntaining vaccine. Frequent bster dses f tetanus and diphtheria txids may lead t severe lcal and systemic reactins and may be assciated with high levels f circulating antitxin. Nte: In rder t prvide prtectin fr pertussis Alberta Health recmmends prviding dtap regardless f spacing since last dse f Td. There is n mnvalent acellular pertussis vaccine available in Canada at this time. Pssible Reactins Cmmn: Pain, redness and swelling at the injectin site, usually mild and transient in duratin. Headache, fever, tiredness, generalized bdy ache, sre/swllen jints, chills, nausea, vmiting, diarrhea, anrexia, rash, axillary lymph nde swelling and myalgia. Rare: Severe lcal reactins ccur rarely and may be assciated with high levels f circulating tetanus antitxin. Rarely, increased sweating, pruritus, allergic reactins and anaphylaxis were reprted. The fllwing additinal adverse events have been reprted frm pstmarketing surveillance: urticaria, pruritus, anaphylaxis, neurlgical cmplicatins, musculskeletal and cnnective tissue disrders. Anaphylaxis. As with any immunizatin, unexpected r unusual side effects can ccur. Refer t the prduct mngraph fr mre detailed infrmatin. Pregnancy Lactatin dtap may be ffered t pregnant wmen 26 weeks gestatin r greater if indicated (See Indicatins Sectin). During utbreak situatins, the zne MOH may authrize use f dtap vaccine with each pregnancy fr pregnant wmen 26 weeks gestatin r greater. Immunizatin during pregnancy requires careful cnsideratin f the risks frm the disease versus the benefit f vaccine. Adequate human data n the use f dtap during pregnancy is nt currently available hwever; inactivated vaccines and txids are usually cnsidered safe fr the fetus. Can be administered t eligible breastfeeding wmen. Cmpsitin Each 0.5 ml dse cntains: Each 0.5 ml dse cntains: Immunizatin Prgram Standards Manual Page 4 f 7
5 Bld/Bld Prducts Bvine/Prcine Prducts Latex Adacel Active Ingredients: tetanus txid - 5 Lf diphtheria txid - 2 Lf five purified acellular pertussis antigens: pertussis txid (PT) µg filamentus haemagglutinin (FHA) 5 µg pertactin (PRN) 3 µg fimbriae types 2 and 3 (FIM) - 5 µg Nn-medical Ingredients: aluminum phsphate (adjuvant) 1.5 mg 2-phenxyethanl 0.6% v/v Trace amunts f: frmaldehyde glutaraldehyde Des nt cntain human bld/bld prducts. Bvine-derived materials are cmpnents in the prductin prcess. Bvine cells are remved during purificatin f the vaccine. Prcine prducts are used in the early manufacturing prcess. Des nt cntain latex. Active Ingredients: tetanus txid - 5 Lf diphtheria txid - 2 Lf three purified acellular pertussis antigens: pertussis txid (PT) - 8 µg filamentus haemagglutinin (FHA) 8 µg pertactin (PRN) 2.5 µg Nn-medical Ingredients: aluminum (as aluminum salts) sdium chlride water fr injectin Residues: disdium phsphate frmaldehyde glutaraldehyde glycine mnptassium phsphate plysrbate 80 ptassium chlride Animal bld (including equine-derived bld) is used as a raw material in the manufacturing prcess. Des nt cntain human bld r bld prducts. Ingredients f animal rigin including bvine, equine and prcine derived materials are used as raw materials in the manufacturing prcess. Interchangeability Administratin with Other Prducts dtap vaccines may be used interchangeably prvided the apprpriate dse and schedule recmmended by the manufacturer are used. May be given at the same time as ther inactivated and live vaccines using a separate needle and syringe fr each vaccine. The same limb may be used if necessary, but different sites n the limb must be chsen. If dtap and TIG are given at the same time fr wund management, use separate anatmic sites (different limbs) fr each injectin. Appearance Shake vial well t prduce a unifrm, cludy suspensin. Shake well in rder t btain a hmgeneus turbid white suspensin. Immunizatin Prgram Standards Manual Page 5 f 7
6 Strage Stre at +2 0 C t +8 0 C. D nt freeze. D nt use beynd the labeled expiry date. Stre in riginal packaging when pssible t prtect frm light. Vaccine Cde Antigen Cde Licensed fr dtap Tetanus T Diphtheria D Acellular pertussis - P Licensed fr bster immunizatin fr individuals 4 years f age and lder. In Alberta, dtap vaccine has been apprved fr ff license use fr a primary series fr individuals 7 years up t and including 17 years f age. Ntes: dtap vaccine was implemented as the reinfrcing dse fr students in Grade 9 as f September 1, dtap vaccine was implemented fr the fllwing adult ppulatins n February 1, 2012: healthcare wrkers prviding care t children under 12 mnths f age adults wh have nt received an adlescent r adult dse f dtap vaccine as they present fr service. In July 2014 an adult dse f dtap was implemented regardless f previus histry f adlescent dtap vaccine. Related Resurces: Diphtheria, Tetanus, Acellular Pertussis Vaccine Infrmatin Sheet (104516). Immunizatin Prgram Standards Manual Page 6 f 7
7 References: Adacel 1. Alberta Health, (2017, September 20). Alberta Health, Public Health and Cmpliance Divisin Alberta Immunizatin Plicy - Bilgical Prducts - dtap 2. Alberta Health. (2014, January). Alberta Immunizatin Plicy. Adverse Event Fllwing Immunizatin (AEFI) Plicy fr Alberta Health Services Public Health. Alberta Health. 3. Alberta Health. (2007, Nvember). Public Health and Cmpliance Divisin Alberta Immunizatin Plicy Adverse Events. Fllwing Immunizatin Interpretatin f DAT and TAT Levels 4. Centers fr Disease Cntrl and Preventin. (2011). General Recmmendatins n Immunizatin: Recmmendatins f the Advisry Cmmittee n Immunizatin Practices. Mrbidity and Mrtality Weekly Reprt, 60 (2), Centers fr Disease Cntrl and Preventin. Preventing Tetanus, Diphtheria and Pertussis Amng Adults: Use f Tetanus Txid, Reduced Diphtheria Txid and Acellular Pertussis Vaccine: Recmmendatins f the Advisry Cmmittee n Immunizatin Practices. Mrbidity and Mrtality Weekly Reprt, 55 (17). 6. Centers fr Disease Cntrl and Preventin. Updated Recmmendatins fr Use f Tetanus Txid, Reduced Diphtheria Txid and Acellular Pretussis Vaccine (Tdap) in Pregnant Wmen and Persns Wh Have r Anticipate Having Clse Cntact with an Infant Aged < 12 Mnths: Recmmendatins f the Advisry. Mrbidity and Mrtality Weekly Reprt, 60 (41). 7. GlaxSmithKline. (2018, March 5). Prduct Mngraph. Bstrix: Cmbined Diphtheria, Tetanus, Acellular Pertussis (Adsrbed) Vaccine fr Bster Vaccinatin. 8. Grabenstein, J. D. (2013). ImmunFacts: Vaccines and Immunlgic Drugs (38th Revisin ed.). St. Luis, MO: Wlters Kluwer Health. 9. Natinal Advisry Cmmittee n Immunizatin. (2012). Canadian Immunizatin Guide (Evergreen Editin). Ottawa, ON: Public Health Agency f Canada. 10. Natinal Advisry Cmmittee n Immunizatin. (2005). Interval Between Administratin f Vaccines Against Diphtheria, Tetanus and Pertussis. Canada Cmmunicable Disease Reprt, 31 (ACS-9). 11. Natinal Advisry Cmmittee n Immunizatin. (2003). Preventin f Pertussis in Adlscents and Adults. Canada Cmmunicable Disease Reprt, 29 (ACS-5). 12. Natinal Advisry Cmmittee n Immunizatin. (2000). Statement n Adult/Adlscent Frmulatin f Cmbined Acellular Pertussis, Tetanus and Diphtheria Vaccine. Canada Cmmunicable Disease Reprt, 26 (ACS-1). 13. Sanfi Pasteur Limited. (2012, June 11). Prduct Mngraph. Adacel: Tetanus Txid, Reduced Diphtheria Txid and Acellular Pertussis Vaccine Adsrbed. Immunizatin Prgram Standards Manual Page 7 f 7
Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib-HB)
Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Pli-Haemphilus Influenzae type b Cnjugate Cmbined Vaccine Bilgical Page (DTaP-IPV-Hib-HB) Sectin 7: Bilgical Prduct Infrmatin Standard #: 07.214 Created
More informationDiphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib-HB)
Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Pli-Haemphilus Influenzae type b Cnjugate Cmbined Vaccine Bilgical Page (DTaP-IPV-Hib-HB) Sectin 7: Bilgical Prduct Infrmatin Standard #: 07.214 Created
More informationBOOSTRIX -POLIO: Diphtheria-Tetanus- Acellular Pertussis-Polio Combined Vaccine Biological Page (dtap-ipv)
BOOSTRIX -POLIO: Diphtheria-Tetanus- Acellular Pertussis-Polio Combined Vaccine Biological Page (dtap-ipv) Section 7: Biological Product Information Standard #: 07.213 Created by: Province-wide Immunization
More informationHepatitis B Vaccine Biological Page
Hepatitis B Vaccine Bilgical Page Sectin 7: Bilgical Prduct Infrmatin Standard #: 07.234 Created by: Apprved by: Prvince-wide Immunizatin Prgram Standards and Quality Prvince-wide Immunizatin Prgram, Standards
More informationDiphtheria-Tetanus-Acellular Pertussis-Polio- Combined Vaccine Biological Page (DTaP-IPV)
Diphtheria-Tetanus-Acellular Pertussis-Polio- Combined Vaccine Biological Page (DTaP-IPV) Section 7: Biological Product Information Standard #: 07.212 Created by: Province-wide Immunization Program Standards
More informationTetanus Prevention, Prophylaxis and Wound/Injury Management Standard
Tetanus Preventin, Prphylaxis and Wund/Injury Management Standard Sectin 8: Immunizatin f Special Ppulatins Standard #: 08.400 Created by: Apprved by: Prvince-wide Immunizatin Prgram, Standards and Quality
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationSection IA-Introduction
Immunizatin Prgrams and Vaccine Preventable Diseases Service 655 West 12th Avenue Vancuver, BC V5Z 4R4 Tel 604.707.2548 Fax 604.707.2515 www.bccdc.ca Date: May 15, 2017 Administrative Circular: 2017:07
More informationDiphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib)
Diphtheria-Tetanus-Acellular Pertussis-Polio- Haemophilus influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib) Section 7: Biological Product Information Standard #: 07.211 Created
More informationVaccine Information Statement: PNEUMOCOCCAL CONJUGATE VACCINE
Vaccine Infrmatin Statement: PNEUMOCOCCAL CONJUGATE VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están
More informationVaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE
Vaccine Infrmatin Statement: LIVE INTRANASAL INFLUENZA VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están
More informationMedical Student Immunization Requirements
Medical Student Immunizatin Requirements The State f Illinis cde, Reference: (110 ILCS 20) Cllege Student Immunizatin Act, requires students t prvide prf f immunity: Measles (Rubela), Mumps, Rubella (German
More informationSafety of HPV vaccination: A FIGO STATEMENT
FIGO Statement n HPV Vaccinatin Safety, August 2nd, 2013 Safety f HPV vaccinatin: A FIGO STATEMENT July, 2013 Human papillmavirus vaccines are used in many cuntries; glbally, mre than 175 millin dses have
More informationChildhood Immunization Status (NQF 0038)
Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December
More informationProvider Information: Influenza VISs
Prvider Infrmatin: Influenza VISs Thirteen influenza vaccine prducts are apprved fr use in the United States fr the 2014-15 influenza seasn: Name Manufacturer Age Range # f Strains Afluria bicsl 9 years
More informationPolio Vaccine Biological Page
Polio Vaccine Biological Page Section 7: Biological Product Information Standard #: 07.300 Created by: Approved by: Province-wide Immunization Program Standards and Quality Province-wide Immunization Program,
More informationDear Student, IMMUNIZATION RECORD INSTRUCTIONS
Dear Student, Welcme t the University f Chicag! The State f Illinis and University regulatins require students t prvide prf f required immunizatins prir t registratin fr classes. In rder t cmplete this
More informationHPV VACCINATION IN SANDYFORD SERVICES
HPV VACCINATION IN SANDYFORD SERVICES 1. General infrmatin n HPV Vaccinatin 2. HPV vaccinatin in females 3. Yung Wmen Only 4. HPV vaccinatin in MSM 1. General infrmatin General Infrmatin fr clinicians
More informationFlu Season Key Points ( )
2014-2015 Flu Seasn Key Pints (10-31-14) Cntents Overarching Framewrk f CDC Influenza Messaging... 3 Take 3 Messages... 3 Statements fr General Audiences... 4 Disease... 4 Vaccinatin... 6 Vaccinatin Timing...
More informationENA Topic Brief. Adult Immunizations. Key Information
ENA Tpic Brief Key Infrmatin Immunizatins are vital fr d isease preventin and health prmtin. The CDC prvides recmmendatins fr adult immunizatins. Infrmatin n vaccines are available at n cst frm the CDC.
More informationChildhood Immunization Status (NQF 0038)
Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December
More informationPediatric and adolescent preventive care and HEDIS *
Pediatric and adlescent preventive care and HEDIS * * HEDIS is a registered trademark f the Natinal Cmmittee fr Quality Assurance (NCQA). UniCare Health Plan f West Virginia, Inc. Healthcare Effectiveness
More informationAlberta Health Public Health Notifiable Disease Management Guidelines April 2013
April 2013 Hepatitis A Revisin Dates Case Definitin Reprting Requirements Remainder f the Guideline (i.e., Etilgy t References sectins inclusive) Updated Prphylaxis Table and Algrithm (Pages 9, 12) Case
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationCDC Influenza Division Key Points November 7, 2014
In this dcument: Summary Key Messages FluView Activity Update LAIV Effectiveness and Vaccinatin f Children H3N2 Match and Vaccinatin Vaccine Supply Summary Key Messages This week s FluView reprt indicates
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More information77 WHO/IPA workshop on Immunisation
77 WHO/IPA wrkshp n Immunisatin cst/efficacy f either f them des nt justify their rutine use. Cntents f such diseases shuld be within the respnsibilities f the Epidemilgy Department. XVII INTERNATIONAL
More informationImmunisation and Disease Prevention Policy
Immunisatin and Disease Preventin Plicy Quality Area 2: Children s Health and Safety 2.1 Each child s health is prmted 2.1.4 Steps are taken t cntrl the spread f infectius diseases and t manage injuries
More informationCDC Influenza Division Key Points MMWR Updates February 20, 2014
CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. Over the last several mnths, the United States has experienced a natinwide utbreak f entervirus D68 (EV- D68) assciated
More informationHuman papillomavirus (HPV) refers to a group of more than 150 related viruses.
HUMAN PAPILLOMAVIRUS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between
More informationThe pages that follow contain information critical to protecting the health of your patients and the citizens of Colorado.
Health Alert Netwrk Tri-Cunty Health Department Serving Adams, Arapahe and Duglas Cunties Phne 303/220-9200 Fax 303/741-4173 www.tchd.rg Richard L. Vgt, M.D. Executive Directr The pages that fllw cntain
More informationGUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH
GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting
More informationH1N1 Influenza 09 Guidance for Residential Aged Care
H1N1 Influenza 09 Guidance fr Residential Aged Care 11 June 2009 As knwledge abut H1N1 Influenza 09 develps, further advice will be prvided. Please check www.healthemergency.gv.au fr the latest infrmatin.
More informationInfluenza (Flu) Fact Sheet
Influenza (Flu) Fact Sheet What is the flu? The flu is a cntagius respiratry illness caused by influenza viruses. It can cause mild t severe illness, and at times can lead t death. Sme peple, such as lder
More informationPART III: CONSUMER INFORMATION
IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr ZERIT Stavudine This leaflet is Part III f a three-part Prduct Mngaph published when ZERIT was apprved fr sale in Canada and is designed specifically
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationImplementation of G6PD testing and radical cure in P. vivax endemic countries: considerations
Implementatin f G6PD testing and radical cure in P. vivax endemic cuntries: cnsideratins Malaria Plicy Advisry Cmmittee Geneva, Switzerland 16-18 September 2015 1 WHO Guidelines n Radical Cure WHO guidelines
More informationFDA Dietary Supplement cgmp
FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes
More informationMeasles. CLINICAL CASE DEFINITION An illness characterized by all of the following: CASE CLASSIFICATION Suspect: Rash illness with fever
CLINICAL CASE DEFINITION An illness characterized by all f the fllwing: Measles a generalized rash lasting at least 3 days AND a temperature f 101 F (38.3C) r higher AND at least ne f: cugh, cryza (runny
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationSECTION O. MEDICATIONS
SECTION O. MEDICATIONS 1. NUMBER OF MEDICA TIONS (Recrd the number f different medicatins used in the last 7 days; enter "0" if nne used) O1. Number f Medicatins (7-day lk back) Intent: Prcess: Cding:
More informationCDC Influenza Technical Key Points February 15, 2018
CDC Influenza Technical Key Pints In this dcument: Summary Key Pints U.S. Vaccine Effectiveness U.S. Flu Activity Update Summary Key Pints On Thursday, tw influenza-related reprts appeared in the Mrbidity
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. The United States is currently experiencing a natinwide utbreak f entervirus D68 (EV-D68) assciated with severe
More informationTick fever is a cattle disease caused by any one of the following blood parasites:
Tick fever Tick fever is a cattle disease caused by any ne f the fllwing bld parasites: Babesia bvis Babesia bigemina Anaplasma marginale These parasites are all transmitted by the cattle tick (Bphilus
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
(Sanfi-Aventis France), NT001 Suppliers submissin f the SRA apprved text Octber 2016 Name f the medicinal prduct Text bx PACKAGE LEAFLET: INFORMATION FOR THE USER NOTEZINE 100 mg, scred tablets Diethylcarbamazine
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationPATIENT INFORMATION. effective for the treatment of the flu in people with long-time (chronic) heart problems or breathing problems.
PATIENT INFORMATION capsules, fr ral use fr ral suspensin What is TAMIFLU? TAMIFLU is a prescriptin medicine used t: treat the flu (influenza) in peple 2 weeks f age and lder wh have had flu symptms fr
More informationHospital Preparedness Checklist
Hspital Preparedness Checklist http://pandemicflu.gv Preparedness Subject 1. Structure fr planning and decisin making An internal, multidisciplinary planning cmmittee fr influenza preparedness has been
More informationIowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training
Iwa Early Peridic Screening, Diagnsis and Treatment Care fr Kids Prgram Prvider Training The Early Peridic Screening, Diagnsis and Treatment (EPSDT) Care fr Kids prgram is Iwa s Medicaid prgram fr children.
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationTriumeq (abacavir, dolutegravir and lamivudine) Product Backgrounder for US Media
Triumeq (abacavir, dlutegravir and lamivudine) Prduct Backgrunder fr US Media What is Triumeq and wh is Triumeq fr? Triumeq (abacavir 600mg, dlutegravir 50mg and lamivudine 300mg) is the first dlutegravir-based
More informationDear University of Chicago Student,
Dear University f Chicag Student, The state f Illinis and the University f Chicag require students t have prf f immunity fr certain diseases including Measles (Rubela), Mumps, Rubella (German Measles)
More informationOsteoporosis Fast Facts
Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased
More informationRequest for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax
Request fr Prir Authrizatin fr Click here t enter text. Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 Updated: 05/2018 DMMA Apprved: 05/2018 All requests fr Intravenus
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationBRCA1 and BRCA2 Mutations
BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease
More informationBenepali (etanercept): Brief training on additional Risk Minimisation Measures
Benepali (etanercept): Brief training n additinal Risk Minimisatin Measures Slide Deck fr Healthcare Prfessinal (HCP) Training Versin 9.0; 22 January 2016 UK/IE 1 Benepali (etanercept) This medicine is
More informationMinistry of Health and Long-Term Care
Ministry f Health and Lng-Term Care Infrmatin n Nvel H1N1 Influenza A - Frequently Asked Questins fr Primary Care Practitiners May 7, 2009 This infrmatin is subject t change based n evlving infrmatin n
More informationImmunization for Special Populations
Newfundland and Labradr Immunizatin Manual Sectin 8 Immunizatin fr Special Ppulatins 8.1 Immunizatin Pst Bne Marrw Transplant/Stem Cell Transplant... 1-1 8.2 Immunizatin f Asplenic Ppulatin... 2-1 8.3
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.
More informationPneumococcal 13-valent Conjugate Vaccine Biological Page
Pneumococcal 13-valent Conjugate Vaccine Biological Page Section 7: Biological Product Information Standard #: 07.291 Created by: Province-wide Immunization Program Standards and Quality Approved by: Province-wide
More informationWidening of funding restrictions for rituximab and eltrombopag
20 February 2014 Widening f funding restrictins fr rituximab and eltrmbpag PHARMAC is pleased t annunce the apprval f prpsals t widen the restrictin n rituximab use in DHB hspitals and expand the funding
More informationAcellular Pertussis Vaccines Developed in Japan and Their Application for Disease Control
S264 Acellular Pertussis Vaccines Develped in Japan and Their Applicatin fr Disease Cntrl Tatsu Ayama Pediatric Departments, Kawasaki Municipal Hspital, Kawasaki, and Schl fmedicine, Kei University, Tky,
More informationLow Molecular Weight Heparin Prescribing and Administration (Adults)
Clinical guideline Lw Mlecular Weight Heparin Prescribing and Administratin (Adults) The Natinal Patient Safety Agency issued guidance n ways f reducing dsing errrs when prescribing lw mlecular weight
More informationMANITOBA HEALTH, HEALTHY LIVING & SENIORS WEEKLY WEST NILE VIRUS SURVEILLANCE REPORT (WEEK 27)
MANITOBA HEALTH, HEALTHY LIVING & SENIORS WEEKLY WEST NILE VIRUS SURVEILLANCE REPORT (WEEK 27) The weekly West Nile Virus Surveillance Reprt utlines the mst current surveillance data and is psted weekly
More informationPolicy Guidelines: Genetic Testing for Carrier Screening and Reproductive Planning
Plicy Guidelines: Genetic Testing fr Carrier Screening and Reprductive Planning Cntents Overview... 1 Cverage guidelines... 2 General cverage guidelines... 2 Rutine carrier screening... 2 Carrier screening
More informationThe estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by
ESTIMATION PROCEDURES USED TO PRODUCE WEEKLY FLU STATISTICS FROM THE HEALTH INTERVIEW SURVEY James T. Massey, Gail S. Pe, Walt R. Simmns Natinal Center fr Health Statistics. INTRODUCTION In April 97, the
More informationAnnual Principal Investigator Worksheet About Local Context
Cmpleting the NCI CIRB Annual Principal Investigatr Wrksheet Abut Lcal Cntext and the Study-Specific Wrksheet Abut Lcal Cntext at the University f Iwa All investigatrs cnducting research with the Natinal
More informationLyme Disease Surveillance in North Carolina
Lyme Disease Surveillance in Nrth Carlina 2008-2014 Carl Williams DVM Megan Sanza MPH Cmmunicable Disease Branch Divisin f Nrth Carlina Public Health Lyme Disease Surveillance in Nrth Carlina 2008-2014
More informationOccupational Hazards in Home Health Care. Blood Borne Pathogens
Occupatinal Hazards in Hme Health Care Bld Brne Pathgens Healthcare persnnel are at risk fr ccupatinal expsure t bldbrne pathgens, including hepatitis B virus (HBV), hepatitis C virus (HCV), and human
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationThe principles of evidence-based medicine
The principles f evidence-based medicine By the end f this mdule yu shuld be able t: Describe what evidence based medicine is Knw where t find quality evidenced based medicine n the internet Be able t
More informationYear 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:
Year 10 Fd Technlgy Assessment Task 1: Fds fr Special Needs Name: Teacher: Due Date: Term 2, Week 1 Type f Task: Design Task Planning Fd Requirements Cllectin f Assessment: Submit in Class Assessment Plicy:
More informationMethadone Maintenance Treatment for Opioid Dependence
POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin
More informationSection V: Immunization
Michigan Lcal Public Health Accreditatin Prgram Tl 2014 MPR Indicatr Guide Sectin V: Immunizatin MPR 1 The lcal health department shall ffer immunizatin services t the public fllwing a cmprehensive plan
More informationMEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion
MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injectin fr intravenus infusin Read this Medicatin Guide befre yu start receiving LEMTRADA and befre yu begin each treatment curse. There may be new
More informationPackage leaflet: Information for the user. Fragmin Graduated Syringe 10,000 IU/ml Solution for Injection dalteparin sodium
Package leaflet: Infrmatin fr the user Fragmin Graduated Syringe 10,000 IU/ml Slutin fr Injectin dalteparin sdium Read all f this leaflet carefully befre yu start using this medicine because it cntains
More informationRoActemra (tocilizumab) for Giant Cell Arteritis (GCA) subcutaneous (SC) formulation
RActemra (tcilizumab) fr Giant Cell Arteritis (GCA) subcutaneus (SC) frmulatin What yu shuld knw abut RActemra This brchure prvides key infrmatin t assist in the patient s understanding f the benefits
More informationTO: Mayor & Council DATE: March 8, The Planning & Development Department and the Legal Services Division recommend that Council:
CORPORATE REPORT NO: R049 COUNCIL DATE: March 12, 2018 REGULAR COUNCIL TO: Mayr & Cuncil DATE: March 8, 2018 FROM: SUBJECT: General Manager, Planning & Develpment City Slicitr, Legal Services Cannabis
More informationPackage leaflet: Information for the user. Dacepton 5 mg/ml Solution for infusion Apomorphine hydrochloride hemihydrate
Package leaflet: Infrmatin fr the user Daceptn 5 mg/ml Slutin fr infusin Apmrphine hydrchlride hemihydrate Read all f this leaflet carefully befre yu start using this medicine because it cntains imprtant
More informationSection 6 Students School District No. 71 (Comox Valley)
Sectin 6 Students Schl District N. 71 (Cmx Valley) Administrative Prcedure 6011 MR2 Allergies and Anaphylaxis 1. Intrductin The Bard f Educatin expects schls t reasnably accmmdate students with medically
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment
More information2017 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationHumanities and Social Sciences Division. o Work Experience, General. o Open Entry/Exit. Distance (Hybrid Online) for online supported courses
SECTION A - Curse Infrmatin 1. Curse ID: 2. Curse Title: 3. Divisin: 4. Department: 5. Subject: 6. Shrt Curse Title: 7. Effective Term:: SIGN 108 Fingerspelling Humanities and Scial Sciences Divisin Sign
More informationMeasures to Minimize Influenza Transmission at Swine Exhibitions
Measures t Minimize Influenza Transmissin at Swine Exhibitins It is estimated that 150 millin peple visit agricultural fairs each year in Nrth America. Agricultural exhibitins prvide valuable educatinal
More informationGuidelines for the Admission of Children and Young People with an Eating Disorder
Guidelines fr the Admissin f Children and Yung Peple with an Eating Disrder This dcument is designed t be used by clinicians lcated in hspitals f wards withut specialist eating disrder facilities, t guide
More informationOriginal Policy Date 12:2013
MP 5.01.18 Xlair (Omalizumab) Medical Plicy Sectin Prescriptin Drugs Issu12:2013e 4:2006 Original Plicy Date 12:2013 Last Review Status/Date Lcal plicy/12:2013 Return t Medical Plicy Index Disclaimer Our
More informationChapter 6: Impact Indicators
Overview Chapter 6: Impact Indicatrs The best measure f the lng-term impact f all HIV preventin activities is the HIV incidence rate, namely the number f new cases f HIV infectin per year divided by the
More informationHepatitis B Immune Globulin Biological Page
Hepatitis B Immune Globulin Biological Page Section 7: Biological Product Information Standard #: 07.233 Created by: Approved by: Province-wide Immunization Program Standards and Quality Province-wide
More informationObesity/Morbid Obesity/BMI
Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin
More informationEAGLE CARE A SPORT CLUB CONCUSSION MANAGEMENT MODEL
EAGLE CARE A SPORT CLUB CONCUSSION MANAGEMENT MODEL Cncussin awareness has increased significantly in recent years. The Natinal Cllegiate Athletic Assciatin (NCAA), Natinal Athletic Trainers Assciatin
More informationAssessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams
Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.
More informationBLOOD BORNE PATHOGENS
BLOOD BORNE PATHOGENS GALVESTON ISD ANNUAL TRAINING 2018-2019 Galvestn Independent Schl District Special Prgrams/ECH Health Services Required Training Ò Training is required by the Texas Department f Health
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More information2016 CWA Political Action Fund Administrative Procedures Checklist
2016 CWA Plitical Actin Fund Administrative Prcedures Checklist 1. Dates f Prgram The 2016 CWA Plitical Actin Fund (federal plitical actin cmmittee- CWA-COPE PCC) Prgram will be cnducted n a calendar year
More informationZika Virus. Where has Zika virus been found? Zika in the United States and its territories:
Where has Zika virus been fund? Zika Virus Prir t 2015, Zika virus utbreaks have ccurred in areas f Africa, Sutheast Asia, and the Pacific Islands. In May 2015, the Pan American Health Organizatin (PAHO)
More informationCLINICAL MEDICAL POLICY
Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019
More informationDiabetes: HbA1c Poor Control (NQF 0059)
Diabetes: HbA1c Pr Cntrl (NQF 0059) EMeasure Name Diabetes: HbA1c Pr Cntrl EMeasure Id Pending Versin Number 1 Set Id Pending Available Date N infrmatin Measurement January 1, 20xx thrugh Perid December
More informationFee Schedule - Home Health Care- 2015
Fee Schedule - Hme Health Care- 2015 01/01/2015 1600 E Century Ave Ste 1 PO Bx 5585 Bismarck ND 58506-5585 www.wrkfrcesafety.cm Cpyright Ntice The five character cdes included in the Nrth Dakta Fee Schedule
More information